Plasma‐derived C1 esterase inhibitor vs placebo or active control
Adverse events(during · children or adults with Types I or II HAE
Plasma‐derived C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).
1 finding from 1 review
- Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes onlyRR 1.05 [0.78, 1.42]1 study · 71 participantsLow